Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -4 of 4
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
4/1/2002
 
First Published:
11/1/1999
1.
Phase I/II Study of Yttrium Y 90-Labeled Humanized Anti-CD22 Monoclonal Antibody LL2 in Patients with B-Cell Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
18 and over
NCI
CMMI-C-037A-97
NCI-H99-0041, NCI-V99-1567, NCT00004084
Last Modified:
4/1/2002
 
First Published:
11/1/1999
2.
Phase I/II Study of Radioimmunotherapy with High Dose Yttrium Y 90 Humanized Anti-CD22 Monoclonal Antibody LL2 Followed By Autologous Peripheral Blood Stem Cell Rescue in Patients with B Cell Lymphomas or Waldenstrom's Macroglobulinemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
18 to 80
NCI
CMMI-C-037B-97
UPCC-1499, NCI-H99-0040, NCT00004107
3.
Safety Study of NHL With 90Y-hLL2 IgG
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
Over 18
Pharmaceutical / Industry
IM-T-hLL2-06EU
NCT00421395
Last Modified:
12/1/2001
 
First Published:
12/1/1999
4.
Phase I Study of Yttrium Y 90 Humanized Anti-CD22 LL2 in Combination With Salvage Chemotherapy and Autologous Peripheral Blood Stem Cell Rescue in Patients With Recurrent or Refractory B-Cell Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
Other
CMMI-C-037C-97
NCI-V99-1569, NCT00004086
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute